Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high262.00 04/10/16
52 week low88.00 16/09/16
52 week change 93.50 (92.12%)
4 week volume453,103 30/06/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics plc : Grant of Share Options and Restricted Stock Units

Summit Therapeutics plc: Grant of Share Options and Restricted Stock Units Summit Therapeutics plc ('Summit' or the 'Company') GRANT OF SHARE OPTIONS TO DIRECTORS, PDMRS AND EMPLOYEES AND GRANT OF RESTRICTED STOCK UNITS TO NON-EXECUTIVE DIRECTORS Oxford, UK, 19 July 2017 - Summit Therapeutics plc (AIM: SUMM, ...

Summit Therapeutics plc : Result of AGM

Summit Therapeutics plc: Result of AGM Summit Therapeutics plc ('Summit' or 'the Company') RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infect...

Summit Therapeutics plc : Grant of Share Options

Summit Therapeutics plc: Grant of Share Options Summit Therapeutics plc ("Summit" or the "Company") GRANT OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces ...

Summit Therapeutics plc : Exercise of Share Options

Summit Therapeutics plc: Exercise of Share Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, annou...

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT PRESENTS DATA FROM PHASE 1 CLINICAL PROGRAMME OF EZUTROMID AT THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY CONGRESS Oxford, UK, 22 June 2017 - Summit Therapeu...

Four AIM shares for a post-election world

Given UK political uncertainty, former AIM writer of the year Andrew Hore names companies exposed to overseas earnin...

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 15 June 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...

Summit losses fall

Summit Therapeutics has reported a loss for the three months ended 30 April 2017 of 4.8m, compared to a loss of 5.4m for ...

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Re: NEW ARTICLE: Four AIM shares for a p...

    ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...
    6-Jul-2017
    bobsson
  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...
    18-Jun-2017
    pharmaspecialist
  • NEW ARTICLE: Four AIM shares for a post-election world

    "Weakening retail figures and the post-election uncertainty are not a great backdrop for UK-focused companies.The Conservatives have, at the moment, not completed a deal with ...
    16-Jun-2017
    II Editor

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
RANGE RES.20%
LLOYDS GRP.20%
ROYAL BANK SCOT17%
SIRIUS MINERALS14%
TESCO13%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM